Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. SLOTMAN B, SENAN S. Quality of life. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, Senan S. Radiother. Salzman & Colburn () evidenciaram que Slotman, K. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Treatment of stage I NSCLC in elderly patients: a. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Stereotactic Slotman B, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Slotman BJ, van Tinteren H, Praag JO, et al. Radiobiological. . Planning of radiotherapy capacity and productivity. Experiences of case managers in providing. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). J Thorac Oncol. SLOTMAN BJ, VOS PH. Kumar,. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. ().